View in EDS

Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.

Saved in:
Bibliographic Details
Title: Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.
Authors: Bissonnette R; Innovaderm Research Inc., Montreal, Quebec, Canada. Electronic address: rbissonnette@innovaderm.com., Stein Gold L; Henry Ford Health System, Detroit, Michigan., Kircik L; Icahn School of Medicine at Mount Sinai, New York, New York., Simpson EL; Oregon Health & Science University, Portland, Oregon., Eichenfield LF; University of California San Diego and Rady Children's Hospital, San Diego, California., Browning J; Texas Dermatology and Laser Specialists, San Antonio, Texas., Hebert AA; UTHealth McGovern School of Medicine and Children's Memorial Hermann Hospital, Houston, Texas., Alexis AF; Weill Cornell Medicine, New York, New York., Soong W; AllerVie Health and Clinical Research, Birmingham, Alabama., Piscitelli SC; Formerly of Dermavant Sciences, Inc., Morrisville, North Carolina., Tallman AM; Dermavant Sciences, Inc., Morrisville, North Carolina., Rubenstein DS; Formerly of Dermavant Sciences, Inc., Morrisville, North Carolina., Brown PM; Dermavant Sciences, Inc., Morrisville, North Carolina., Silverberg JI; The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2025 Sep; Vol. 93 (3), pp. 707-714. Date of Electronic Publication: 2025 May 16.
Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40383273
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bissonnette+R%22">Bissonnette R</searchLink>; Innovaderm Research Inc., Montreal, Quebec, Canada. Electronic address: rbissonnette@innovaderm.com.<br /><searchLink fieldCode="AU" term="%22Stein+Gold+L%22">Stein Gold L</searchLink>; Henry Ford Health System, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Kircik+L%22">Kircik L</searchLink>; Icahn School of Medicine at Mount Sinai, New York, New York.<br /><searchLink fieldCode="AU" term="%22Simpson+EL%22">Simpson EL</searchLink>; Oregon Health & Science University, Portland, Oregon.<br /><searchLink fieldCode="AU" term="%22Eichenfield+LF%22">Eichenfield LF</searchLink>; University of California San Diego and Rady Children's Hospital, San Diego, California.<br /><searchLink fieldCode="AU" term="%22Browning+J%22">Browning J</searchLink>; Texas Dermatology and Laser Specialists, San Antonio, Texas.<br /><searchLink fieldCode="AU" term="%22Hebert+AA%22">Hebert AA</searchLink>; UTHealth McGovern School of Medicine and Children's Memorial Hermann Hospital, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Alexis+AF%22">Alexis AF</searchLink>; Weill Cornell Medicine, New York, New York.<br /><searchLink fieldCode="AU" term="%22Soong+W%22">Soong W</searchLink>; AllerVie Health and Clinical Research, Birmingham, Alabama.<br /><searchLink fieldCode="AU" term="%22Piscitelli+SC%22">Piscitelli SC</searchLink>; Formerly of Dermavant Sciences, Inc., Morrisville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Tallman+AM%22">Tallman AM</searchLink>; Dermavant Sciences, Inc., Morrisville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Rubenstein+DS%22">Rubenstein DS</searchLink>; Formerly of Dermavant Sciences, Inc., Morrisville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Brown+PM%22">Brown PM</searchLink>; Dermavant Sciences, Inc., Morrisville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Silverberg+JI%22">Silverberg JI</searchLink>; The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227907132%22">Journal of the American Academy of Dermatology</searchLink> [J Am Acad Dermatol] 2025 Sep; Vol. 93 (3), pp. 707-714. <i>Date of Electronic Publication: </i>2025 May 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mosby%22">Mosby </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7907132 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-6787 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201909622%22">01909622 </searchLink><i>NLM ISO Abbreviation: </i>J Am Acad Dermatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40383273
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaad.2025.05.1391
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 707
    Titles:
      – TitleFull: Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bissonnette R
      – PersonEntity:
          Name:
            NameFull: Stein Gold L
      – PersonEntity:
          Name:
            NameFull: Kircik L
      – PersonEntity:
          Name:
            NameFull: Simpson EL
      – PersonEntity:
          Name:
            NameFull: Eichenfield LF
      – PersonEntity:
          Name:
            NameFull: Browning J
      – PersonEntity:
          Name:
            NameFull: Hebert AA
      – PersonEntity:
          Name:
            NameFull: Alexis AF
      – PersonEntity:
          Name:
            NameFull: Soong W
      – PersonEntity:
          Name:
            NameFull: Piscitelli SC
      – PersonEntity:
          Name:
            NameFull: Tallman AM
      – PersonEntity:
          Name:
            NameFull: Rubenstein DS
      – PersonEntity:
          Name:
            NameFull: Brown PM
      – PersonEntity:
          Name:
            NameFull: Silverberg JI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2025 Sep
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1097-6787
          Numbering:
            – Type: volume
              Value: 93
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Journal of the American Academy of Dermatology
              Type: main
ResultId 1